Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Versatility and nuances of the architecture of haematopoiesis - Implications for the nature of leukaemia.
Brown G, Hughes PJ, Ceredig R, Michell RH.
Leuk Res. 2012 Jan;36(1):14-22. Epub 2011 Nov 8. Review.
Related citations
Immune-mediated peripheral neuropathy occurring simultaneously with recurrent graft-versus-host disease after allogenic hematopoietic stem cell transplantation.
Doi Y, Sugahara H, Yamamoto K, Uji-ie H, Kakimoto T, Sakoda H.
Leuk Res. 2012 Apr;36(4):e63-5. Epub 2011 Dec 17. No abstract available.
The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation.
Tanaka M, Kobayashi S, Numata A, Tachibana T, Takasaki H, Maruta A, Ishigatsubo Y, Kanamori H.
Leuk Res. 2012 Jun;36(6):699-703. Epub 2011 Dec 14.
Allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials.
Zhang H, Chen J, Que W.
Leuk Res. 2012 Apr;36(4):431-7. Epub 2011 Nov 1.
Cooperation between somatic Ikaros and Notch1 mutations at the inception of T-ALL.
Sontani Y, Chapman G, Papathanasiou P, Dunwoodie S, Goodnow CC, Hoyne GF.
Leuk Res. 2011 Nov;35(11):1512-9. Epub 2011 Aug 15.
Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood.
Krishnadas DK, Stamer MM, Dunham K, Bao L, Lucas KG.
Leuk Res. 2011 Nov;35(11):1520-6. Epub 2011 Jul 19.
An unusually long survival without stem cell transplantation after the blast crisis phase of chronic myeloid leukemia: a case report.
Choi Y, Yang Y, Beom SH, Park S.
Leuk Res. 2012 Jan;36(1):e25-6. Epub 2011 Oct 11. No abstract available.
The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation.
Holroyd A, Cross NC, Macdonald DH.
Leuk Res. 2011 Oct;35(10):1279-85. Epub 2011 Jul 1. Review.
Elevated Fas/FasL system and endothelial cell microparticles are involved in endothelial damage in acute graft-versus-host disease: a clinical analysis.
Wu Q, Chen H, Fang J, Xie W, Hong M, Xia L.
Leuk Res. 2012 Mar;36(3):275-80. Epub 2011 Sep 13.
Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: association with disease characteristics and variation in different cell compartments.
Udi J, Wider D, Kleber M, Ihorst G, Müller A, Wäsch R, Engelhardt M.
Leuk Res. 2011 Sep;35(9):1265-8.
Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: induction of IL-10 expression in the stromal layers.
Lazarini M, Traina F, Winnischofer SM, Costa FF, Queiroz ML, Saad ST.
Leuk Res. 2011 Aug;35(8):1102-7. Epub 2011 Apr 20.
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
Sayar H, Chan RJ, Orschell CM, Chan EM, Yu Z, Hood D, Plett A, Yang Z, Hui CL, Nabinger SC, Kohlbacher KJ, West ES, Walter A, Sampson C, Wu J, Cripe LD.
Leuk Res. 2011 Aug;35(8):1108-10. Epub 2011 Mar 21.
Hammada scoparia flavonoids and rutin kill adherent and chemoresistant leukemic cells.
Bourogaa E, Bertrand J, Despeaux M, Jarraya R, Fabre N, Payrastre L, Demur C, Fournié JJ, Damak M, Feki AE, Racaud-Sultan C.
Leuk Res. 2011 Aug;35(8):1093-101. Epub 2011 Jan 8.
ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia.
Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ.
Leuk Res. 2011 Oct;35(10):1390-4. Epub 2011 Aug 2.
Genetic disruption of the scaffolding protein, Kinase Suppressor of Ras 1 (KSR1), differentially regulates GM-CSF-stimulated hyperproliferation in hematopoietic progenitors expressing activating PTPN11 mutants D61Y and E76K.
Yang Z, Chen M, Sitarski SA, Saadatzadeh T, Yin F, Yu M, Yang FC, Chan RJ.
Leuk Res. 2011 Jul;35(7):961-4. Epub 2011 May 8.
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Nagi W, Lim ZY, Krishnamurthy P, Potter V, Tindell V, Reiff-Zall L, Abdullah A, Lea N, Kenyon M, Marsh J, Ho AY, Mufti GJ, Pagliuca A.
Leuk Res. 2011 Aug;35(8):998-1000. Epub 2011 Jun 24.
High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2.
Chamuleau ME, Ossenkoppele GJ, van Rhenen A, van Dreunen L, Jirka SM, Zevenbergen A, Schuurhuis GJ, van de Loosdrecht AA.
Leuk Res. 2011 Jun;35(6):741-9. Epub 2011 Feb 1.
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
Arcaini L, Laszlo D, Rizzi S, Balzarotti M, Antoniazzi F, Zilioli VR, Guggiari E, Farina L, Todisco E, Bonfichi M, Alamos SM, Rossi G, Martinelli G, Morra E.
Leuk Res. 2011 Jun;35(6):712-4. Epub 2011 Jan 26.
PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia.
Brobeil A, Bobrich M, Graf M, Kruchten A, Blau W, Rummel M, Oeschger S, Steger K, Wimmer M.
Leuk Res. 2011 Oct;35(10):1367-75. Epub 2011 Apr 22.
The clonogenic potential of selected CD34+ cells from patients with MDS appear preserved when tested ex vivo.
Davison GM, Novitzky N, Abdulla R.
Leuk Res. 2011 Sep;35(9):1200-4. Epub 2011 Apr 6.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on